AU Health partners with Inflo Health to elevate the radiology follow-up process to optimize the patient experience

CONTACT: Lisa Kaylor, AU Health, 706-755-3160, lkaylor@augusta.edu ; Alicia Laszewski, Inflo Health, 954-683-7189, alicia@yourbrandethos.com

AUGUSTA, Ga. (June 13, 2023) – Augusta University Health (AU Health), a comprehensive primary, specialty, and subspeciality healthcare network based in Augusta, Georgia, that serves as the primary teaching affiliate for the Medical College of Georgia , announced today that they are partnering with Inflo Health , a radiology follow-up solution powered by advanced AI and natural language understanding (NLU). Augusta University Health will leverage Inflo Health’s innovative solution to automate the radiology follow-up process for hundreds of thousands of their radiology patients per year.

According to an American College of Radiology study, 60% of radiology imaging follow-ups never get completed. Inflo Health estimates that their platform allows their customers the ability to recapture at least 80% of these missed follow-ups.

“The radiology follow-up process can be challenging and time intensive, with life-changing consequences,” added John Crossgrove, Director of Radiology Services at AU Health. “Inflo Health is a smart and powerful technology that stood out to us during our search for a partner in this area for a multitude of reasons. The ability to automate and close the communication loop with 100% of our providers and patients in this area, across all modalities, without adding additional staff is transformational in supporting our world-class patient care mission and objectives.”

Inflo Health will support all areas within AU Health’s radiology program, including support to close any gaps within the incidental findings program. According to the ACR, incidental findings are defined as “an incidentally discovered mass or lesion, detected by CT, MRI, or other imaging modality performed for an unrelated reason.” Many different forms of cancers are discovered incidentally, and lifesaving therapies can be prescribed much earlier in the tumor development, leading to better patient outcomes.

Dr. Annette Johnson, AU Health’s Chair of Radiology and Imaging commented, “Complexity within health systems contributes to the reality that communication breakdowns are responsible for the majority of safety events in health care environments.  Test results management is a particularly substantial challenge for physicians and other providers, despite their diligence and focused efforts at information management.  Breakdowns in communication of test results occur across the spectrum of clinical settings and can result in delayed diagnoses and harm to patients. Our vision in AU Health Radiology is ‘Better imaging for better health.’ By partnering with Inflo Health, we can further this vision by creating automated processes for identification and tracking of imaging findings that require follow-up—so that we can have a failsafe system for providing timely and potentially life-saving testing and treatment to further ensure the delivery of the very best care for our patients. We are thrilled to have selected Inflo Health as our partner on this journey.”

Angela Adams, CEO of Inflo Health, said, “A recent article published by the American College of Radiology (ACR) cited that over 65% of Emergency Physicians and Radiologists report that their health systems do not have a tracking mechanism for incidental findings today. This is a staggering statistic given the importance of timely identification and communication for healthy patient outcomes. Augusta University Health is an innovative health system, and we are proud to partner with them on this mission-critical enhancement to their radiology team and their patients.” 

Inflo Health was founded by a revolutionary radiologist, frustrated by an overworked and inefficient healthcare system, who wanted to improve the patient outcomes. As a result, a team of clinical and technical experts came together to develop large language models and NLU to read and understand radiology reports with the goal of automating identification of which patients have recommendations for additional imaging. Inflo Health then automates communication to the care team and to the patients to help ensure the follow-ups are ordered and scheduled. The Inflo Health platform streamlines the management of radiology follow-up recommendations across all imaging modalities.

About Inflo Health: We harness the power of advanced AI, large language models, and NLU to turn radiology follow-up into a stress-free process. Our proven, automated solution streamlines the management of follow-up recommendations across all imaging modalities, so you can ensure no patient falls through the care gap. With our easy-to-use, integrated platform, your team can focus on delivering top-quality patient care, while also mitigating risk, and maximizing staff efficiency.

###

AU Health is Georgia’s only public academic health center, where world-class clinicians are bringing the medicine of tomorrow to patient care today. As the primary teaching affiliate of the Medical College of Georgia, AU Health provides the most comprehensive routine-to-complex care at AU Medical Center, which houses the region’s only Level 1 trauma center, as well as Children’s Hospital of Georgia, Georgia Cancer Center, historic Roosevelt Warm Springs Rehabilitation and Specialty Hospitals, Georgia War Veterans Nursing Home, and more than 100 primary and specialty care clinics across the state.

April 4, 2026
April 2, 2026- WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) , released the following statement on Section 232 Pharmaceutical Proclamation. “A thriving American biotechnology ecosystem is essential to growing the U.S. economy, strengthening national security, and improving the health and well‑being of everyday Americans. While we appreciate the Administration’s recognition of the need for tariff exemptions for certain critical biotech products, the reality is that any tariffs on America’s medicines will raise costs, impede domestic manufacturing, and delay the development of new treatments - all while doing nothing to enhance our national security. “U.S. biotech companies have been eager to expand investments here at home, but tariffs, along with an uncertain policy environment and efforts to force “most‑favored nation” schemes, work directly against that goal. The risks are especially acute for small and mid‑size biotech companies, which develop more than half of all FDA‑approved medicines yet often lack the capital to build dedicated manufacturing facilities as they weather an industry defined by high costs, long development timelines, and significant risk. “The fact is: tariffs divert scarce resources away from research and development, weaken American biotech against China’s rising industry, and ultimately, harm health and economic wellbeing of Americans. “We stand ready to work with the Administration on a long‑term strategy that encourages biotechnology investment, reduces the time, cost, and uncertainty of developing new medicines, expands U.S. biomanufacturing capacity, and ensures American innovation is fairly valued overseas. Tariffs and MFN are not the answer." Source - https://www.bio.org/press-release/bio-statement-section-232-pharmaceutical-proclamation
April 1, 2026
Atlanta, GA (April 1, 2026) – Georgia Life Sciences (GLS) is proud to announce that Saisurya Lakkimsetti, a junior at Lakeside High School in Columbia County, has been named the winner of the 2026 Georgia BioGENEius Challenge. The Georgia BioGENEius Challenge took place, as part of the statewide Georgia Science and Engineering Fair (GSEF) at the Classic Center in Athens, Georgia. Forty-seven students from across Georgia competed for this year’s title and cash prize. Jaehyeon Lee, an 11th-grade student from Walton High School, was named runner-up in this year’s competition. The Georgia BioGENEius Challenge recognizes outstanding high school students who are conducting innovative biotechnology research with real-world applications. This year’s top projects, presented in the Global Healthcare Challenge track, demonstrated exceptional scientific rigor and forward-thinking potential in addressing critical healthcare challenges. Saisurya’s research focuses on identifying potential inhibitors for Endocan, a protein known to play a role in glioblastoma tumor growth. Using advanced computational modeling techniques—including AlphaFold and molecular docking tools—she screened thousands of small molecules to identify compounds that may block tumor-promoting signaling pathways. Her work identified several promising candidates that could serve as a foundation for future drug development targeting glioblastoma. Jaehyeon’s project investigates how varying glucose concentrations affect regeneration in planaria, modeling impaired wound healing in diabetic conditions. By testing graded glucose environments and measuring regeneration indicators such as growth and differentiation, Jaehyeon demonstrated that lower glucose levels enhance regeneration while higher levels inhibit healing. The study establishes a model to better understand hyperglycemia’s impact on diabetic wound healing. “The work by these students is a powerful example of the innovation and determination we see in Georgia’s next generation of life sciences leaders,” said Maria Thacker Goethe, President and CEO of Georgia Life Sciences. “The BioGENEius Challenge is critical because it provides students with a platform to apply cutting-edge science to real-world problems, while also strengthening the future workforce that will drive breakthroughs in healthcare, biotechnology, and beyond.” The Georgia BioGENEius Challenge is part of Georgia Life Sciences’ broader commitment to advancing workforce development and fostering innovation across the state’s rapidly growing life sciences ecosystem. Judging the 2026 Georgia BioGENEius Challenge: Ian Biggs; Ralph Cordell, CDC; Alex Harvey, ViaMune; Jamie Graham, Smith Gambrell Russell; and Evan Scullin, LuminiSci.
March 24, 2026
Georgia Life Sciences is thrilled to be featured in the very first Atlanta edition of Inside Medicine . This inaugural issue represents something truly special. Atlanta’s healthcare and life sciences community is driven by innovation, collaboration, and outstanding leadership—and we’re honored to be part of this exciting launch. Also in the issue, GLS's Kennedy Dumas is featured, sharing her journey on how observation and research evolved into a powerful practice of journaling. As the founder of Stationery Black, she creates notebooks designed to showcase, uplift, and inspire people of color. Read the full article here.
MORE POSTS